DossierENTITY

Kartos

Coverage of Kartos in the Nexus archive.

Earliest in view: Jun 29 · 14:00 UTCMost recent: Jun 29 · 14:00 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSJun 29 · 14:00 UTCQUARTZ
Ipsen is buying U.S. blood cancer startup Kartos for up to $1.75 billion
Ipsen, a French drugmaker, is acquiring U.S. blood cancer startup Kartos for up to $1.75 billion, with a $450 million upfront payment. Kartos is developing a late-stage drug for myelofibrosis.